1Yang WY, Lu JM, Weng JP. Prevalence of Diabetes among Men and Women in China[J]. N Engl J Med, 2010, 362: 1090-1101.
2Pan C, Yang W, Jia W, et al. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys[J]. Curr Med Res Opin, 2009, 25:39- 45.
3Jonassen lB. Insulin Degludec is a New generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer Formation[J]. Diabetes, 2010, 59(Suppl.1): 39-OR.
4Heise Z Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions[J]. Diabetologia, 2010, 53(Suppl1 ): 971.
5Birkeland KI, Home PD, Wendiscb U, et al. Insulin degludec in type J diabetes: a randomized controlled trial of a new-generation ultra-long acting insulin compared with insulin glargine[J]. Diabetes Care, 34(3): 661-665.
6Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial[J]. Lancet, 2011,377(9769): 924-931.
